Combination Effects Following Addition of the Tumour-Vascular Disrupting Agent ASA404 (Vadimezan) to Taxane-Containing Regimens of Trastuzumab and Bevacizumab in Human Breast Cancer Xenograft Models.
2013 ◽
Vol 73
(15)
◽
pp. 4885-4897
◽
2012 ◽
Vol 136
(3)
◽
pp. 673-682
◽
2014 ◽
Vol 55
(10)
◽
pp. 1692-1698
◽
2010 ◽
2020 ◽
2006 ◽
Vol 4
(12)
◽
pp. 66
◽
2019 ◽
Vol 42
(11)
◽
pp. 1921-1925
◽